Tests a new combination for older adults with diffuse large B-cell lymphoma

Trial details

Who runs it

Nordic Lymphoma Group

Trial code

NCT04332822EU 2022-502887-19-00

Record updated

19 September 2024

Original description

This is a phase III, randomized, open-label, multicenter trial, conducted in Sweden, Norway, Finland, Denmark, Italy, Australia and New Zealand, in elderly patients with untreated diffuse large B-cell lymphoma. Elderly is defined as either ≥80 years of age, or ≥75 years and frail, according to a simplified Comprehensive Geriatric Assessment. Patients will be randomized 1:1 to either the standard treatment for this population, R-miniCHOP, or an experimental regimen, R-pola-miniCHP, where vincristine is substituted by an immunoconjugate, polatuzumab vedotin. The duration of the screening period is up to 4 weeks. The duration of active treatment is 18 weeks in both arms, and patients will be followed up to 36 months after end of treatment. Start of enrollment is planned in Q1 2020, and the last visit of the last patient included (end of trial) is estimated in Q1 2027.Read full original descriptionShow less

R-MINI-CHOP Versus R-MINI-CHP in Combination With Polatuzumab-vedotin, as Primary Treatment for Patients With Diffuse Large B-cell Lymphoma, ≥80 Years, or Frail ≥75 Years - an Open Label Randomized Nordic Lymphoma Group Phase III Trial

This is a phase III, randomized, open-label, multicenter trial, conducted in Sweden, Norway, Finland, Denmark, Italy, Australia and New Zealand, in elderly patients with untreated diffuse large B-cell lymphoma. Elderly is defined as either ≥80 years of age, or ≥75 years and frail, according to a simplified Comprehensive Geriatric Assessment. Patients will be randomized 1:1 to either the standard treatment for this population, R-miniCHOP, or an experimental regimen, R-pola-miniCHP, where vincristine is substituted by an immunoconjugate, polatuzumab vedotin. The duration of the screening period is up to 4 weeks. The duration of active treatment is 18 weeks in both arms, and patients will be followed up to 36 months after end of treatment. Start of enrollment is planned in Q1 2020, and the last visit of the last patient included (end of trial) is estimated in Q1 2027.

Inclusion: Age ≥80 years or frail ≥75 years, according to simplified comprehensive geriatric assessment; Histologically confirmed lymphoma belonging to one of the following subtypes:; diffuse large B-cell lymphoma, including transformation from an indolent lymphoma; follicular lymphoma grade 3B; T-cell/histiocyte-rich LBCL; primary cutaneous DLBCL, leg type; EBV-positive DLBCL, NOS; primary mediastinal LBCL; high grade B-cell lymphoma with MYC/BCL2 rearrangement; Stage II-IV disease; At least 1 measurable site of disease (>1.5 cm long axis); No previous treatment for lymphoma; WHO performance status 0 - 3 (Grade 3 if related to DLBCL); Written informed consent.

Exclusion: Severe cardiac disease: NYHA grade 3-4; Uncontrolled serious infection; Any other prior malignancy than non-melanoma skin cancer or stage 0 (in situ) cervical carcinoma, unless treated with curative intent, and without relapse since 2 years, or low grade prostate cancer, not in need of treatment; Psychiatric illness or condition which could interfere with their ability to understand the requirements of the study; Known hypersensitivity to rituximab, polatuzumab vedotin, cyclophosphamide, vincristine or doxorubicin, or HACA against rituximab; Impaired liver (transaminases > 3x normal upper limit or bilirubin > 1.5 x normal upper limit, unless due to Gilbert´s syndrome) , renal (GFR<30ml/min) or other organ function not caused by lymphoma, which will interfere with the treatment; Absolute neutrophil count (ANC) <1000 cells/µL or platelets <100,000 cells/µL, unless due to lymphoma; CNS involvement at diagnosis; Peripheral neuropathy grade ≥ 2.

ClinicalTrials.gov NCT04332822 · EU CTIS 2022-502887-19-00